Navigation Links
Finding Points to Possible Blood Test for Brain Tumors
Date:11/17/2008

Tiny sacs, released by glioblastoma cells, can be detected, study shows

MONDAY, Nov. 17 (HealthDay News) -- Researchers have stumbled across a novel mechanism by which brain tumors model their environment to nurture their own growth.

The findings expose a fundamental biological process of which oncologists were previously unaware, and which may one day be exploited to combat glioblastoma, experts said. But just as significantly, they provide a potential means to monitor cancer progression and treatment by a simple blood test, rather than having to rely on either brain imaging or biopsies -- something that currently is not possible.

"Wouldn't it be awesome to know that a tumor is not fully treated or recurring before you ever see it on an X-ray or an MRI?" mused Dr. Paul Graham Fisher, a neuro-oncologist at Stanford University. "Or even beyond that, I mean, this gets way down the road, could you do a blood test to detect a brain tumor? That would be just awesome."

In findings reported in the Nov. 16 issue of Nature Cell Biology, Xandra Breakefield of Massachusetts General Hospital, and her team, led by Johan Skog, report that glioblastoma cells secrete small membrane-enclosed sacs called microvesicles. Filled with proteins and genetic material, these vesicles are picked up by neighboring cells in the brain, where they apparently induce them to alter their gene expression program to suit the needs of the tumor. Specifically, these cells can be coaxed into forming new blood vessels to supply nutrients to the growing cancer mass.

"We think the tumor cells bud off these vesicles filled with information, genetic and protein information, to actually take over their environment," said Breakefield. "I mean, they are doing it for a purpose, and they're doing it with a vengeance."

In fact, the tumors secrete so many of these vesicles that they can be found in the patient's bloodstream, outside the brain. When Skog analyzed the protein and RNA content of these microvesicles (also called exosomes) in the blood samples of glioblastoma patients, he found that he could obtain a sort of molecular snapshot of the tumor.

"By analyzing the RNA in these serum exosomes, we could determine the mutational profile in the tumor without doing a biopsy," explained Skog. "So, this is an enabling technology to look at what's going on inside the tumor at a given moment."

Like all cancers, glioblastoma cells often contain dozens of mutations. One of these, called EGFRvIII, is a mutation in the gene for a growth factor receptor called EGFR. Skog first screened 30 glioblastoma biopsies for the presence of EGFRvIII; he found it in 14 samples. When he examined blood samples from the same patients, he was able to detect the mutation in 7 samples, including two corresponding to biopsy samples that had come back negative for EGFRvIII.

That particular observation made quite an impression on Fisher. "They were really good at showing that a lot of the tumors that expressed [EGFRvIII], they were able to find it in these microvesicles in the blood, and you go, 'wow'," he said. "And then, even on top of that, they found a few tumors where they weren't able to find it, but we know that EGFRvIII is very specific to glioblastoma in a patient like this, and they were able to find it in the blood but not in the tumor, and you go, 'Hot darn, that's just incredible'."

It may therefore one day be possible to test blood samples from glioblastoma patients to monitor patient progress, check for recurrence, and make individualized treatment decisions. For instance, said Breakefield, one current chemotherapeutic is a monoclonal antibody that specifically targets the EGFRvIII mutation. "Obviously, those people would respond better to this if they had that mutation," she said.

More remotely, it may one day be possible to run early screens for the occurrence of cancer long before symptoms arise, when the cancer may be, if not curable, at least more amenable to treatment.

At the moment, the only way to assess the genetic profile of glioblastoma is via brain biopsy. And the only way to detect a brain tumor noninvasively is using brain imaging, such as by MRI or PET scans. Often, by the time patients develop symptoms of glioblastoma, the disease is so advanced as to be incurable, and often, inoperable.

Other cancer types also apparently extrude microvesicles, including breast cancer, suggesting these findings may be generalizable to other solid tumors. But, "we were the first to show for any cancer that you could pick up a mutated RNA in the exosomes of the cancer," Breakefield said.

According to statistics from the National Cancer Institute, about 22,000 Americans will be diagnosed this year with some form of brain or other nervous system tumor; 13,000 brain cancer patients will die this year. Earlier this year, U.S. Sen. Ted Kennedy (D-Mass.) was diagnosed with malignant glioma.

"I think [this study] represents a novel finding and potentially a major breakthrough in the way we measure gene expression in tumors and the ease by which it can be done by simply a blood test," said Dr. John Yu, Director of Surgical Neuro-Oncology at Cedars-Sinai Medical Center, Los Angeles.

First, however, these findings will have to be validated, and their clinical relevance established, cautioned Dr. Jeremy Rich of the Cleveland Clinic, in Ohio. "There's a lot of work that needs to be done in the interval, but to say that little parts of the tumor basically are being given off, and that we can assess those, is a pretty exciting concept," Rich said.

Concluded Fisher, "You have to mitigate the enthusiasm, because it is the first time through, and there are a lot of things that are first-time-through that don't pan out. But as I was reading this, I thought, this is awesome, it really is capitalizing on a new avenue of research in oncology."

More information

For more on glioblastoma, visit the National Cancer Institute.



SOURCES: Xandra Breakefield, Ph.D., professor, neurology, Harvard Medical School, and geneticist, Massachusetts General Hospital, Boston; Johan Skog, Ph.D., instructor, neurology, Harvard Medical School, and assistant in neurology, Massachusetts General Hospital, Boston; Jeremy N. Rich, M.D., chairman, Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Ohio; John S. Yu, M.D., director, surgical neuro-oncology, Cedars-Sinai Medical Center, Los Angeles; Paul Graham Fisher, M.D., associate professor, neurology and pediatrics, chief, division of child neurology, and The Beirne Family Director of Neuro-Oncology, Stanford University, Palo Alto, Calif.; Nov. 16, 2008, Nature Cell Biology, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. First Family Will Have Tough Time Finding Hypoallergenic Dog
2. Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation
3. Medicaid Health Plans of America Congratulates President-Elect Barack Obama on His Historic Victory and Pledges Its Full Cooperation on Finding Solutions to the Nations Health Care Challenges
4. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
5. NABP Findings Underscore Dangers of Purchasing Prescription Medicine Online and From Foreign Sources
6. New National Public Opinion Survey Reveals Important Findings on Oral Health Care Perceptions
7. LegalView Reintroduces its Medical Malpractice Information Portal with Updated Links to Finding Immediate Legal Assistance
8. New findings may improve treatment of inherited breast cancer
9. Curemark CEO Presents Autism Findings at Prestigious Neurobiology Conference at Oxford
10. Post-marketing studies finding adverse events in drugs used in children
11. Endoscopic ultrasound highly accurate in evaluating ambiguous radiographic findings of the pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Finding Points to Possible Blood Test for Brain Tumors
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: